TRIPHASIL-28 (ethinyl estradiol; levonorgestrel) by Pfizer. Approved for pregnancy. First approved in 1984.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
TRIPHASIL-28 is an oral combined hormonal contraceptive containing ethinyl estradiol and levonorgestrel in a triphasic dosing regimen delivered across 28 days. It prevents pregnancy through suppression of ovulation and alteration of cervical mucus and endometrial environment. This product represents a foundational contraceptive option for women seeking reliable birth control.
Product is approaching loss of exclusivity in a mature, declining market category; expect team consolidation and transition focus toward generic defense or product line optimization.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Positions linked to TRIPHASIL-28 are limited given the product's approaching LOE and reduced commercial investment. Roles available focus primarily on generic defense, cost optimization, and supply chain management rather than growth-oriented brand building. Career advancement opportunities are constrained; professionals should expect transition planning toward growth-stage products or role specialization in mature product management.
Worked on TRIPHASIL-28 at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.